Based on the currently available study data from IBD and on rheumatic indications, TNF-α inhibitors seem to be safe and effective without a significant maternal or fetal risk (i.e., no increase in the frequency of miscarriages or congenital anomalies, no difference in growth and development) [61,80,81]. The gene discussed is TNF; the disease is inflammatory bowel disease.